Pricing Log in Create free account
Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

19.41 0.54 −2.71%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. (AMRX) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, AMNEAL PHARMACEUTICALS, INC. (AMRX) trades at a EV/EBITDA of 14.3×. Over the past ten years it has ranged from 4.2× (May 2018) to 2,279× (January 2020); the current reading is higher than 63% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 9.7× 2.47%
FY2024 9.5× 17.27%
FY2023 8.1× (58.67%)
FY2022 19.5× 140.90%
FY2021 8.1× (15.14%)
FY2020 9.6× (99.57%)
FY2019 2,230× 7,025.33%
FY2018 31.3× 613.53%
FY2017 4.4× 0.00%
FY2016 4.4× 0.00%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 14.7× 21.29%
Jun 2026 12.1× 26.24%
Mar 2026 9.6× (1.02%)
Dec 2025 9.7× 10.39%
43 more quarters

Against its own ten years

Low 4.2× High 2,279×
Ten-year median 11.4×
Current reading's percentile 63

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. compare 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. 14.3×
LNTH Lantheus Holdings, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated compare 19.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on AMRX